检查伐尼克兰和纳曲酮对酒精使用障碍个体延迟折扣的影响。

IF 2.2 4区 医学 Q3 SUBSTANCE ABUSE
Steven J Nieto, James MacKillop, Wave-Ananda Baskerville, Annabel Kady, Alicia Izquierdo, Lara A Ray
{"title":"检查伐尼克兰和纳曲酮对酒精使用障碍个体延迟折扣的影响。","authors":"Steven J Nieto, James MacKillop, Wave-Ananda Baskerville, Annabel Kady, Alicia Izquierdo, Lara A Ray","doi":"10.1093/alcalc/agaf060","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Individuals with alcohol use disorder (AUD) often exhibit heightened delay discounting, a behavioral marker associated with poor treatment outcomes. Medications such as naltrexone and varenicline influence reward-related decision-making, but their effects on delay discounting remain unclear. This study examined whether these medications influence delay discounting rates.</p><p><strong>Methods: </strong>We conducted a double-blind, randomized, placebo-controlled trial in 34 treatment-seeking adults with AUD. Participants were assigned to naltrexone (50 mg/day), varenicline (2 mg/day), or placebo and completed a two-week medication titration followed by a six-day quit attempt. Delay discounting was assessed at baseline and post-treatment using the Monetary Choice Questionnaire (MCQ). General linear models tested medication effects on post-treatment discounting, controlling for baseline discounting, education, and income.</p><p><strong>Results: </strong>A significant interaction between medication and baseline delay discounting emerged (P = .03; η2 = .67). Among participants with lower baseline discounting, naltrexone reduced delay discounting compared to placebo and varenicline. However, no significant effects were observed in participants with higher baseline discounting. Varenicline did not significantly alter delay discounting compared to placebo.</p><p><strong>Conclusions: </strong>These findings suggest that naltrexone may reduce delay discounting in individuals with AUD, but primarily among those with lower discounting rates. The results highlight the importance of baseline traits in understanding medication effects on decision-making. Given the small sample size, future research should replicate these findings in larger trials and explore whether delay discounting could serve as a biomarker for personalized AUD treatment.</p>","PeriodicalId":7407,"journal":{"name":"Alcohol and alcoholism","volume":"60 6","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452822/pdf/","citationCount":"0","resultStr":"{\"title\":\"Examining the effects of varenicline and naltrexone on delay discounting among individuals with alcohol use disorder.\",\"authors\":\"Steven J Nieto, James MacKillop, Wave-Ananda Baskerville, Annabel Kady, Alicia Izquierdo, Lara A Ray\",\"doi\":\"10.1093/alcalc/agaf060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Individuals with alcohol use disorder (AUD) often exhibit heightened delay discounting, a behavioral marker associated with poor treatment outcomes. Medications such as naltrexone and varenicline influence reward-related decision-making, but their effects on delay discounting remain unclear. This study examined whether these medications influence delay discounting rates.</p><p><strong>Methods: </strong>We conducted a double-blind, randomized, placebo-controlled trial in 34 treatment-seeking adults with AUD. Participants were assigned to naltrexone (50 mg/day), varenicline (2 mg/day), or placebo and completed a two-week medication titration followed by a six-day quit attempt. Delay discounting was assessed at baseline and post-treatment using the Monetary Choice Questionnaire (MCQ). General linear models tested medication effects on post-treatment discounting, controlling for baseline discounting, education, and income.</p><p><strong>Results: </strong>A significant interaction between medication and baseline delay discounting emerged (P = .03; η2 = .67). Among participants with lower baseline discounting, naltrexone reduced delay discounting compared to placebo and varenicline. However, no significant effects were observed in participants with higher baseline discounting. Varenicline did not significantly alter delay discounting compared to placebo.</p><p><strong>Conclusions: </strong>These findings suggest that naltrexone may reduce delay discounting in individuals with AUD, but primarily among those with lower discounting rates. The results highlight the importance of baseline traits in understanding medication effects on decision-making. Given the small sample size, future research should replicate these findings in larger trials and explore whether delay discounting could serve as a biomarker for personalized AUD treatment.</p>\",\"PeriodicalId\":7407,\"journal\":{\"name\":\"Alcohol and alcoholism\",\"volume\":\"60 6\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452822/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alcohol and alcoholism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/alcalc/agaf060\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcohol and alcoholism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/alcalc/agaf060","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

摘要

目的:酒精使用障碍(AUD)患者通常表现出高度的延迟折扣,这是一种与不良治疗结果相关的行为标志。纳曲酮和伐尼克兰等药物影响与奖励相关的决策,但它们对延迟折扣的影响尚不清楚。本研究考察了这些药物是否会影响延迟折现率。方法:我们对34名寻求治疗的成年AUD患者进行了一项双盲、随机、安慰剂对照试验。参与者被分配到纳曲酮(50毫克/天)、伐尼克兰(2毫克/天)或安慰剂组,并完成了为期两周的药物滴定,随后进行了为期六天的戒烟尝试。延迟贴现在基线和治疗后使用货币选择问卷(MCQ)进行评估。一般线性模型检验了药物对治疗后折扣的影响,控制了基线折扣、教育和收入。结果:用药与基线延迟折扣之间存在显著的相互作用(P = 0.03; η2 = 0.67)。在基线折扣较低的参与者中,与安慰剂和伐尼克兰相比,纳曲酮降低了延迟折扣。然而,在基线折扣较高的参与者中没有观察到显著的影响。与安慰剂相比,伐尼克兰没有显著改变延迟折扣。结论:这些发现表明纳曲酮可以降低AUD患者的延迟折扣,但主要是在贴现率较低的患者中。结果强调了基线特征在理解药物对决策的影响方面的重要性。鉴于样本量小,未来的研究应该在更大规模的试验中重复这些发现,并探索延迟折扣是否可以作为个性化AUD治疗的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Examining the effects of varenicline and naltrexone on delay discounting among individuals with alcohol use disorder.

Aims: Individuals with alcohol use disorder (AUD) often exhibit heightened delay discounting, a behavioral marker associated with poor treatment outcomes. Medications such as naltrexone and varenicline influence reward-related decision-making, but their effects on delay discounting remain unclear. This study examined whether these medications influence delay discounting rates.

Methods: We conducted a double-blind, randomized, placebo-controlled trial in 34 treatment-seeking adults with AUD. Participants were assigned to naltrexone (50 mg/day), varenicline (2 mg/day), or placebo and completed a two-week medication titration followed by a six-day quit attempt. Delay discounting was assessed at baseline and post-treatment using the Monetary Choice Questionnaire (MCQ). General linear models tested medication effects on post-treatment discounting, controlling for baseline discounting, education, and income.

Results: A significant interaction between medication and baseline delay discounting emerged (P = .03; η2 = .67). Among participants with lower baseline discounting, naltrexone reduced delay discounting compared to placebo and varenicline. However, no significant effects were observed in participants with higher baseline discounting. Varenicline did not significantly alter delay discounting compared to placebo.

Conclusions: These findings suggest that naltrexone may reduce delay discounting in individuals with AUD, but primarily among those with lower discounting rates. The results highlight the importance of baseline traits in understanding medication effects on decision-making. Given the small sample size, future research should replicate these findings in larger trials and explore whether delay discounting could serve as a biomarker for personalized AUD treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Alcohol and alcoholism
Alcohol and alcoholism 医学-药物滥用
CiteScore
4.70
自引率
3.60%
发文量
62
审稿时长
4-8 weeks
期刊介绍: About the Journal Alcohol and Alcoholism publishes papers on the biomedical, psychological, and sociological aspects of alcoholism and alcohol research, provided that they make a new and significant contribution to knowledge in the field. Papers include new results obtained experimentally, descriptions of new experimental (including clinical) methods of importance to the field of alcohol research and treatment, or new interpretations of existing results. Theoretical contributions are considered equally with papers dealing with experimental work provided that such theoretical contributions are not of a largely speculative or philosophical nature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信